IMPORTANCE Prostate cancer imaging rates appear to vary by health care setting. With the recent extension of the Veterans Access, Choice, and Accountability Act, the government has provided funds for veterans to seek care outside the Veterans Health Administration (VA). It is important to understand the difference in imaging rates and subsequent differences in patterns of care in the VA vs a traditional fee-for-service setting such as Medicare.
Introduction
Reducing guideline-discordant prostate cancer staging imaging is an important national priority.
Minimizing guideline-discordant imaging for men with low-risk prostate cancer is listed as a primary focus for reducing inefficient health care utilization in the Choosing Wisely campaign. [1] [2] [3] Within the context of the Veterans Health Administration (VA) system, the Veterans Access, Choice, and Accountability Act, also known as the Choice Act, was passed in 2014 for the goal of reducing wait times for veterans seeking access to specialized health care services by providing funds for patients to seek care outside the VA. 4 Changes in policy, such as the Choice Act, have unclear implications for the quality and cost-effectiveness of care that patients receive.
Prostate cancer imaging rates appear to vary among veterans depending on patients' ability to seek care outside of the VA health system. Earlier research found higher rates of guideline-discordant prostate cancer imaging among VA patients with low-risk prostate cancer who used Medicare services than among those with no Medicare utilization. 5 Within the VA, physicians typically receive a set salary that does not include financial incentives to provide more health care services. 6 Outside the VA, the fee-for-service model used in Medicare and in most health care systems in the United
States may encourage provision of more health care services 7 because of direct physician reimbursement 8, 9 and patient self-referral. Earlier qualitative work found that physicians practicing at the VA are cognizant of this incentive difference between VA and non-VA practice and acknowledge that their own ordering behavior varies by setting. 10 Many of these additional services that are associated with potential financial incentives may have limited efficacy or even be quantifiably unnecessary. 11 Specifically, it is unclear whether a difference in care patterns among veterans seeking care only through the VA vs through the VA and Medicare would also apply to
Medicare patients with no access to the VA.
The aim of this study was to directly assess the association between quality of health care within the VA health system vs a fee-for-service system (Medicare) by comparing rates of guidelinediscordant and guideline-concordant imaging among patients with prostate cancer. To do this, we categorized patients into 1 of 3 groups: those who received health care through a fee-for-service system (the Medicare-only group), those who received health care through an integrated health system (the VA-only group), and those who received health care through a combination of the 2 systems (VA with some Medicare use; the VA and Medicare group).
Outside the VA health system, there may be higher rates of guideline-discordant prostate cancer imaging, suggesting a trade-off of resources for quality of care in a fee-for-service setting. If the rates of guideline-discordant prostate cancer imaging are actually lower outside the VA health system, it is possible that there is a problem in terms of quality of care in an integrated health system. at autopsy or on the death certificate. We excluded men who died within 3 months after diagnosis and men without utilization of any health benefits in months 2 to 6 after diagnosis, a situation suggesting complete departure from the health care system. 5 In addition, men who received a diagnosis at facilities with a prostate cancer diagnosis volume less than 25 cases per year were eliminated because of the unreliability of clinical data from such institutions. 18 We also excluded men without high-risk features but missing any tumor risk characteristic (prostate-specific antigen [PSA],
Gleason grade, or clinical stage), because we could not confirm the risk classification of these men.
Our primary dependent variable of interest was receipt of any of the following imaging studies:
radionuclide bone scan, computed tomography (CT), or magnetic resonance imaging (MRI).
Guideline concordance was determined on the basis of National Comprehensive Cancer Network (NCCN) recommendations for imaging to stage incident prostate cancer. 19 Receipt of bone scan was considered to be guideline discordant unless a patient had any of the following high-risk characteristics: clinical stage T3 or higher, Gleason score 8 or higher, and PSA level of 20 ng/mL or higher. Receipt of CT or MRI was considered to be guideline discordant unless the patient had a 20% or higher risk of positive lymph nodes, estimated from the Partin tables. 20 Men who met the requirements for bone scan, CT, or MRI were classified as having high-risk prostate cancer, whereas all other men were classified as having low-risk prostate cancer. Two exceptions were made to these rules regarding guideline concordance of imaging. Receipt of CT was considered to be guideline concordant for patients with low-risk prostate cancer if they were undergoing radiation therapy, because CT may have been used for treatment planning rather than for disease staging. 21 In addition, receipt of bone scan by a patient with low-risk prostate cancer was considered to be guideline concordant if the patient had a diagnosis of spinal or pathologic fractures in the 3-month period before prostate cancer diagnosis or until 6 months after prostate cancer diagnosis. 22 Patients with low-risk prostate cancer were classified as guideline discordant if they received an inappropriate bone scan, CT, or MRI. Patients with high-risk prostate cancer were classified as guideline concordant if they received a bone scan, CT, or MRI. It is possible that patients received multiple scans; we did not measure surplus guideline-discordant imaging among patients with low-risk prostate cancer or surplus guideline-concordant imaging among patients with high-risk prostate cancer for this study.
The VA and Medicare claims were reviewed for the period beginning 3 months before diagnosis until cancer treatment initiation, death, or 6 months after diagnosis, whichever was earliest. Patient treatment for prostate cancer was identified using ICD-9 diagnosis codes and categorized on the basis of the earliest treatment date as radical prostatectomy, radiation, or other treatment. Other treatment included androgen deprivation, cryosurgery, and watchful waiting (ie, no treatment found).
Data also included age at diagnosis, race, marital status, geographical region of the institution where the diagnosis was given, clinical stage, PSA level at diagnosis, Gleason score at diagnosis, and diagnosis year. In addition, we analyzed claims for the year before prostate cancer diagnosis to calculate an unweighted Elixhauser comorbidity score. 23 Median household income and proportion of the population with a college degree were identified for each patient's county of residence on the basis of 2010 US Census data. 24 The institution where a diagnosis was given was categorized on the basis of the average number of prostate cancer cases diagnosed per year during the study period as high volume (>99 cases), medium volume (60-99 cases), or low volume (<60 cases).
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Statistical Analysis
We created a multivariable logistic regression model to determine the association between all described covariates and the receipt of imaging, stratified by high-risk and low-risk cancer and clustered by region. All covariates were considered to be theoretically important and thus remained in the model regardless of their level of statistical significance. Because the VA cohort included men younger than 65 years and the Medicare cohort did not, we performed a sensitivity analysis that included only men 65 years and older. We report adjusted risk ratios (RRs) computed from the fitted logistic regression model. Statistical analyses were performed using Stata software (version 12.0; StataCorp). All P values were 2-sided with statistical significance at α = .05. Analysis of the data was completed between March 2016 and February 2018.
Results
The cohort included 98 867 men with incident prostate cancer (mean [SD] age, 70.26 [7. 48] years). Table 1 shows that the majority of the sample (57.3%) were in the Medicare-only group, followed by 28.1% in the VA-only group and 14.5% in the VA and Medicare group. Reflecting current nationwide patterns, 5,25 the majority of the cohort (69.8%) were categorized as having low-risk prostate cancer.
The overall study sample was predominantly white (77.4%), followed by black (17.4%), other races (2.8%), and missing or unknown race (2.3%). The largest age group in the cohort was 75 to 85 years (28.9%), followed by 70 to 74 years (25.9%), 65 to 69 years (25.1%), and 64 years and younger (20.0%). Because we limited the Medicare group to men who were age qualified, this group had no members younger than 65 years. Most of the men in the cohort (62.9%) were married. For all variables across the 3 groups, χ 2 tests revealed statistically significant differences. Results of the sensitivity analysis limited to men 65 years and older revealed no significant differences in the magnitude or direction of the odds ratios from the primary analysis.
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Men With High-Risk Prostate Cancer
The proportion of men with high-risk prostate cancer who received at least 1 imaging test was similar among the 3 health care delivery systems, ranging from 75.3% to 79.0% (P < .001) ( Table 2 ). The rate of guideline-concordant imaging among patients with high-risk prostate cancer was also similar 95% CI, 1.10-1.26) had a statistically significant association with receipt of guideline-concordant imaging among men with high-risk prostate cancer (Table 3) .
Discussion
In this study, we analyzed rates of prostate cancer staging imaging among men with a diagnosis of prostate cancer in 3 types of health care delivery settings. We found that men with low-risk disease were less likely to receive guideline-discordant staging imaging if they received a diagnosis and treatment in the VA exclusively compared with those who received care using Medicare or a combination of VA and Medicare services. Furthermore, dividing our study sample into 3 cohorts based on delivery system revealed a dose-response relationship, with men with low-risk prostate cancer in the VA-only group having the lowest likelihood of guideline-discordant imaging, those in the VA and Medicare group having the next highest likelihood of guideline-discordant imaging, and those in the Medicare-only group having the highest likelihood of guideline-discordant imaging. The VA and Medicare health systems differ in notable ways, including their patient demographics and institutional characteristics, 27-29 but it is possible that the differing financial incentives for physicians between these 2 health care delivery systems contributed to significantly different risks of guideline-concordant imaging among men with low-risk cancer. Although differing financial incentives were associated with differences in the rates of guideline-discordant imaging between the 2 groups, the rate of guideline-discordant imaging among patients with low-risk prostate cancer in the VA was high (45.9%) compared with that in other health care delivery systems without financial incentives for overuse, such as in Sweden, where recent guideline-discordant imaging rates were as low as 3% after an intervention to bring imaging practices in line with guidelines. 30 This finding suggests that factors in addition to financial incentives, such as physician education, culture, and habituation, could also contribute to guideline-discordant prostate cancer imaging rates in the United States.
Disease characteristics were also associated with the receipt of imaging, whether guideline discordant for men with low-risk disease or guideline concordant for men with high-risk disease.
Presentation with higher clinical stage, Gleason grade, or PSA level was associated with men with low-risk prostate cancer receiving presumably unwarranted imaging tests. For men with high-risk disease, only increased Gleason grade was associated with guideline-concordant imaging. These findings suggest that physicians find it difficult to adhere to evidence-based heuristics when faced with test results that approach high-risk levels, even when these test results are not sufficient to categorize the patient as having high-risk disease. 19 There is thus an opportunity to reinforce physician knowledge and confidence in nomograms, such as the updated Partin tables, 31 when making decisions regarding imaging of patients with prostate cancer.
Among men with high-risk disease, we found that the likelihood of receiving guidelineconcordant imaging increased with each calendar year. This finding is encouraging and suggests that health care professionals became more aware across the study period of the importance of imaging in accordance with guidelines to stage more advanced cases of prostate cancer. Because this pattern did not occur among men with low-risk prostate cancer, findings suggest that physician education efforts may need to be targeted specifically with regard to the patients with low-risk prostate cancer.
There are numerous indications that guideline-discordant imaging among men with low-risk prostate cancer is still a salient problem. A 2017 systematic review identified 14 articles on overuse of imaging among patients with low-risk prostate cancer, representing data from 2004 to 2012. 32 In the previous 10 years, there were several published efforts to curb guideline-discordant imaging, some of which have been successful, like the Michigan Urological Surgery Improvement Collaborative, 33 and others which have been less so. 34 Guideline-discordant staging imaging for low-risk prostate cancer continues to be regarded as a Choosing Wisely priority. This study provides important baseline data, highlights a prevalent practice pattern targeted for deimplementation, and may serve as a benchmark for more updated analyses to understand where quality improvement efforts may be successful and where they might be failing.
Strengths and Limitations
Our study is strengthened by the large size of our study sample and the meticulous formation of each of the 3 delivery system cohorts. Because our study included men who received diagnosis and treatment using the VA and Medicare, which are 2 of the largest health care systems in the United
States, 35,36 our results are both reliable and generalizable. By creating a distinct cohort of men who used both the VA and Medicare, we were able to uniquely investigate the relative effectiveness of this commonly used approach to health care utilization.
We conducted our assessment of imaging utilization solely through analyses of claims data, and thus there was an inherent possibility of misclassification bias. professionals have expressed that they alter their imaging practices on the basis of health care
setting. 10 Because we did not study the breakdown of health care professionals with dual appointments among the cohorts, the effect of this practice would be unclear in our results and should be further studied.
Our analysis data ended in 2008 and would benefit from an update to include more recent years. However, we carefully constructed these cohorts from multiple data sources and data sets, which is a time-consuming process with lags in availability, to uncover these important results.
Veterans Health Administration regulatory requirements and new data server requirements to obtain updated data would require more than $50 000 in additional funding support just to obtain the data, before consideration of any analyst time, which is why we have not pursued establishing this data set as a repository. In addition, the approval timeline would be approximately 6 to 9 months, further impeding feasibility. The assembly of multiple data sources, even within the VA, requires complex data use agreements, which is one of the reasons that the analytic data set that we have assembled, although somewhat historical, is uniquely valuable.
Conclusions
In this analysis, which merged 2 large prostate cancer cohorts (VACCR and SEER-Medicare), we found that veterans treated in a VA-only setting received the least amount of guideline-discordant imaging among patients with low-risk prostate cancer, without any significant difference in imaging utilization for patients with high-risk prostate cancer, for whom the imaging was necessary. In addition, although veterans who sought care through both the VA and Medicare would seem to be the most likely to experience the most imaging overuse because of the potential for fragmented care in 2 systems, patients seen in the Medicare-only setting had the most guideline-discordant imaging among patients with low-risk prostate cancer. These results reveal important differences between integrated and fee-for-service health systems regarding guideline concordance and quality of care.
The results also suggest that patients using the Choice Act are likely to experience more utilization of care without a guarantee of improved quality of care. Future research to improve guidelineconcordant care for prostate cancer imaging should consider and explore varying contexts and the role of unique settings of different health care systems. In addition, future studies should consider the cost implications of guideline-discordant imaging and the potential savings from an effort to align practice with evidence.
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